A Phase 3 Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-26
Target enrollment:
Participant gender:
Summary
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.